A Study to Evaluate the Safety and Performance of the Dynalink-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions

Trial Profile

A Study to Evaluate the Safety and Performance of the Dynalink-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2011

At a glance

  • Drugs Everolimus (Primary)
  • Indications Restenosis
  • Focus Therapeutic Use
  • Acronyms STRIDES
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 09 Mar 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 09 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Aug 2008 Actual patient number added (104) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top